Our mission is to accelerate our partner's research programs by developing and executing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities.
We combine scientific rigor with our domain expertise in laboratory automation, informatics, and industry best practices to turn challenging assays into quantitative, reproducible results.

Our services


As a contract research organization (CRO), we provide research services to pharmaceutical/biotech companies and academic organizations in form of fee-for-service work.

  • Assay Development
    and Optimization
  • Quantitative Biology and High-
    Throughput Screening (HTS)
  • In vitro
    Bioactivity Assessment
  • Professional

Assay Development and Optimization

  • Adaptation, miniaturization and automation of client-provided assay protocols
  • De novo design of predictive and quantitative bioactivity assays
  • Advanced cell engineering using high-throughput functional clone selection
  • Automated production of cellular reagents

Why Working with Us?

We are passionate about quality.
We learned biopharmaceutical industry standards from the ground up. A robust set of best practices and skilled staff, paired with lab and tissue culture automation, ensures data quality and reproducibility of results.

We have done it before.
We are seasoned specialists in Lead Discovery across indications, including Oncology, Neuroscience, Inflammation, and Metabolic Disorders. While specializing on predictive, functional assays for challenging targets, e.g. ion channels, transporters, or GPCRs, we are experienced with a wide variety of protein target classes and assay formats.

We value scientific interaction.
Scientific exchange and open communication is key to successful research collaborations. Our small and agile team of subject matter experts is approachable and plays well cross-functionally and internationally.

Research Toolbox

Laboratory Technology

Integrated, scheduled robotics platform combined with de facto standard reader devices and flexible workstations.

Covers a comprehensive spectrum of functional readouts and scales to various complexity and throughput requirements.

Mammalian Cells

Collection of 120 engineered cell lines covering a broad range of transmembrane targets (GPCRs, Ion Channels, Transporters).

Automated tissue culture facility enabling complex cell maintenance protocols or bulk cell production at constant quality.

Small Molecule Library

150,000 small molecule compounds, optimized for lead-likeness and diversity, free of undesirable chemotypes, verified by LC/UV/MS.

siRNA Library

97,000 siRNA sequences targeting the human druggable genome. Different RNA chemistries and intrinsic redundancy to statistically identify false hits.

Our partners



2bind is a provider for biophysical analytical services operating in a fee-for-service business model. Our broad portfolio of biophysical assays for hit identification, validation and characterisation allows our customers to accelerate and streamline key research processes in their early drug discovery programs.


anteris medical

anteris medical

Anteris medical supports the pharmaceutical, biotech and medical device industries globally by managing the development of combination products, medical devices or in vitro diagnostics. Our broad competencies cover compliance, regulatory affairs combined with innovative, resource-efficient solutions for compliant development and technical documentation as well as marketing and sales expertise.


Metrion Biosciences

Metrion Biosciences

Metrion Biosciences is an ion channel focused CRO offering integrated drug discovery services, CiPA compliant cardiac safety profiling, phenotypic assays, translational assays and custom screening services on a fee-for-service or collaboration basis. Metrion’s know-how and breadth of services adds value to drug discovery programs by developing and de-risking ion channel modulators as they progress towards nomination for clinical development.



Nanion Technologies

Nanion is a leading provider of automated patch clamp systems with throughput capabilities ranging from a single cell up to fully automated high throughput screening instruments recording from 384 cells simultaneously. Our portfolio contains furthermore analysis devices for membrane pump and transporter recordings (SURFE²R), bilayer recordings (Orbit), and cell monitoring/contractility measurements (CardioExcyte 96).




Meet us at the 2023 BIO International Convention

Assay.Works will attend the upcoming 2023 BIO International Convention June 5-8, 2023, in Boston, Massachusetts, for partnering opportunities. If you are interesting in meeting Dr. Ralf Schwandner, our CEO, stop by at the German Pavilion, booth #1435, or get in touch using the partnering tool.

» Visit the 2023 BIO International Convention

Logo Partex

The Next Chapter in Our Story

We are excited to announce the acquisition of Assay.Works by Partex N.V., a Digital Pharma platform contributing to the biopharma value chain, from Data to Drugs. Partex is registered in Amsterdam, The Netherlands, and headquartered in Eschborn, Germany.

Joining forces with Partex will allow us to build a stable, long-term perspective by expanding our market reach, leveraging synergies, and continuing to invest in our capabilities.

Business will continue as usual. Assay.Works GmbH will operate as a separate legal entity and our management and scientific team will continue working with you in their current roles.

» Read the Press Release


Assay-ready TRP-Channel Cells as a Tool for Drug Discovery

Transient receptor potential (TRP) channels are important targets for discovering novel drugs in a variety of indications, including neuropathic pain or cancer. Together with our partners AcCELLerate and Nanion, we established the pharmacology of recombinant cell lines expressing TRPA1, TRPM8, TRPV1, TRPV3, or TRPV4, in a fluorescent Ca2+-flux assay as well as automated patch-clamp. The cell lines are available as assay-ready frozen cells and can be used directly after thawing for substance screening or profiling of lead candidates.

» Read the application note

About Us

Assay.Works builds on the legacy of the HTS Center of a leading biopharmaceutical company where we provided assay, screening, and quantitative biology services for drug discovery programs across therapeutic areas with high medical need. During our 16-year tenure, we developed and implemented more than 250 screens spanning all major drug target classes, and generated over 100,000,000 data sets.

Dr. Ralf Schwandner

Dr. Ralf Schwandner

Founder and CEO

Biologist and seasoned Lead Discovery specialist with 18 years of experience in the biopharmaceutical industry. Prior to founding Assay.Works, he served as head of Amgen‘s HTS center of excellence at Regensburg, Germany (Amgen Research GmbH).

Dr. Johannes Knop

Dr. Johannes Knop

Founder and COO

Biochemist with 16 years of industry experience in Lead Discovery. Most recently, he was head of Research Operations at Amgen Research GmbH, where he managed Sample Management, cell-based Lead Profiling, Cell Production, Informatics, and EH&S.


Contact Us

please enable javascript to view

Assay.Works GmbH
Am BioPark 11
93053 Regensburg

T +49 941 2000 1240
F +49 941 2000 1241
please enable javascript to view